iSpecimen 3Q 2026: Revenue $244.03K, EPS ($1.03) — 10-Q Summary

iSpecimen reported 3Q 2026 revenue of $244.03K, up 129% YoY, with specimen count rising 169% to 752. Net loss narrowed 20% due to lower operating expenses. Sales and marketing costs increased 21%, while technology and administrative expenses fell. Quote-to-purchase conversion ratio improved to 44%.

Original reporting
Published Nov 17, 2026, 11:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 11:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
iSpecimen 3Q 2026: Revenue $244.03K, EPS ($1.03) — 10-Q Summary — source image
Decision brief

The 30-second read

$ISPCNeutralMed
01

Why it matters

Traders can use the disclosed operating KPIs (specimen volume, ASP, conversion ratio, expense lines) to reassess near-term burn and the sustainability of growth versus pricing pressure.

02

Market read

A fresh quarterly disclosure with multiple directional operating metrics, but no explicit guidance, keeps the setup more about execution than a definitive re-rating.

03

What to watch

Quote-to-purchase-order conversion improved to 44%, but the article does not quantify absolute order economics or whether sales and marketing growth (up 21%) is efficiently translating into profitable growth.

Relevance 6/10Novelty 6/10Timing: after-hours/filing-day read-through from the Nov. 17, 2026 10-Q

Background

The piece is a 10-Q summary for iSpecimen’s 3Q 2026 results, highlighting revenue, loss, operating expense trends, and conversion metrics.

Company-level read

Ticker impact

$ISPCNeutralMedium confidence
Context

iSpecimen reports 3Q 2026 revenue of $244.03K and EPS of ($1.03), alongside a 129% revenue rise and a 20% narrower net loss.

Expected impact

Likely modest upside bias as investors focus on revenue growth and expense reductions, tempered by continued losses and falling average selling price.

Evidence & confidence

The article provides multiple directional operating metrics (revenue up, net loss narrowed, operating expenses down) but does not include guidance or a clear profitability inflection.

Market effects

Limited broader sector signal; this is a single microcap-style quarterly operating update with no stated industry-wide catalyst.

No clear regional spillover beyond sentiment for small-cap healthcare/biotech-adjacent names.

No direct global macro or cross-border supply-demand linkage described.

Counterpoint

Revenue growth may be driven by higher specimen volume while pricing weakens (average selling price down 15%), which could cap margin expansion.

Key entities

  • iSpecimen Inc.

    Subject of the 3Q 2026 10-Q summary, reporting revenue growth, narrower net loss, and improved quote-to-PO conversion.

Related articles

$ZTEKFMed

Zentek Ltd. (ZTEKF): Financial results for FY2027

Zentek Ltd. (ZTEKF) furnished an SEC Form 6-K — earnings release. Zentek Q2 Fiscal 2027 Results News Release Zentek Strengthens Its Balance Sheet, Ends Second Quarter with $13.6 Million in Cash Working capital of $11.3 million at September 30, 2026, compared with a deficit of $1.3 million at March 31, 2026 Guelph, Ontario, November 16, 2026. Ze

$WBMedAI 8/10

Alibaba Is Pulling Back From This 10% Dividend Stock

Weibo (WB) missed Q3 revenue and earnings expectations, with advertising revenue from Alibaba (BABA) falling 33%. Shares dropped 4% premarket. GAAP net income fell 88.91%, operating cash flow turned negative, and long-term loans were reclassified as current. The dividend yield is 10.6%, but earnings are declining. CEO Gaofei Wang highlighted AI efforts, but ad budgets remain a concern.

$SLSHighAI 9/10

SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.